Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026PRNewsWire · 2 days ago
Contrasting Actinium Pharmaceuticals (NYSE:ATNM) and Cytokinetics (NASDAQ:CYTK)Defense World · 3 days ago
Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate CancerPRNewsWire · 5 days ago
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer ModelsPRNewsWire · 5 days ago
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026PRNewsWire · 6 days ago
Actinium Pharmaceuticals Announces Inducement Grants to New EmployeesPRNewsWire · Oct 16, 2026Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$0.20 | $0.89 | Beat |
| May 8, 2026 | -$0.22 | -$0.18 | Beat |
| Mar 30, 2026 | -$0.19 | -$0.19 | Miss |
| Nov 14, 2025 | -$0.25 | -$0.16 | Beat |
| Aug 8, 2025 | -$0.32 | -$0.22 | Beat |
| May 9, 2025 | -$0.26 | -$0.51 | Miss |